Elevated levels of serum-soluble CD14 in human immunodeficiency virus type 1 (HIV-1) infection: Correlation to disease progression and clinical events

Blood

Volumn 92, Issue 6, 1998, Pages 2084-2092

  Lien, Egil ^a   Aukrust, Pål ^b   Sundan, Anders ^b   Müller, Fredrik ^b   Frøland, Stig S ^b   Espevik, Terje ^b  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CD14 ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; DISEASE SEVERITY; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; LYMPHOCYTE FUNCTION; MYCOBACTERIUM AVIUM; PATHOGENESIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 0032530736     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.6.2084.418k26_2084_2092     Document Type: Article

References (61)

1. Esser R, von Briesen H, Brugger M, Ceska M, Glienke W, Muller S, Rehm A, Rubsamen Waigmann H, Andreesen R: Secretory repertoire of HIV-infected human monocytes/macrophages. Pathobiology 59:219, 1991
2. Swartz RP, Roecklein JA, Pierce PF Jr, Yeager H Jr: Altered in vitro handling of Mycobacterium avium complex by monocytes and serum fromHIV( + ) patients. Immunol Invest 24:987, 1995
3. Ziegler Heitbrock HW, Ulevitch RJ: CD14: Cell surface receptor and differentiation marker. Immunol Today 14:121, 1993
4. Haziot A, Tsuberi BZ, Goyert SM: Neutrophil CD14: Biochemical properties and role in the secretion of tumor necrosis factor-alpha in response to lipopolysaccharide. J Immunol 150:5556, 1993
5. Frey EA, Miller DS, Jahr TG, Sundan A, Bazil V, Espevik T, Finlay BB, Wright SD: Soluble CD14 participates in the response of cells to lipopolysaccharide. J Exp Med 176:1665, 1992
6. Hailman E, Lichenstein HS, Wurfel MM, Miller DS, Johnson DA, Kelley M, Busse LA, Zukowski MM, Wright SD: Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD 14. J Exp Med 179:269, 1994
7. Jahr TG, Sundan A, Lichenstein HS, Espevik T: Influence of CD 14, LBP and BPI in the monocyte response to LPS of different polysaccharide chain length. Scand J Immunol 42:119, 1995
8. Hailman E, Vasselon T, Kelley M, Busse LA, Hu MC, Lichenstein HS, Detmers PA, Wright SD: Stimulation of macrophages and neutrophils by complexes of Hpopolysaccharide and soluble CD14. J Immunol 156:4384, 1996
9. Schutt C, Schilling T, Kruger C: sCD14 prevents endotoxin inducible oxidative burst response of human monocytes. Allerg Immunol lleipz 37:159, 1991
10. Haziot A, Rong G-W, Bazil V, Silver J, Goyert SM: Recombinant soluble CD14 inhibits LPS-induced tumor necrosis factor-α production by cells in whole blood. J Immunol 152:5868, 1994
11. Vita N, Lefort S, Sozzani P, Reeb R, Richards S, Borysiewicz PF, Labeta MO: Detection and biochemical characteristics of the receptor for complexes of soluble CD14 and bacterial lipopolysaccharide. J Immunol 158:3457, 1997
12. Soell M, Lett E, Holveck F, Schöller M, Wachsmann D, Klein J-P: Activation of human monocytes by streptococcal rhamnose glucose polymers is mediated by CD14 antigen, and mannan binding protein inhibits TNF-α release. J Immunol 154:851, 1995
13. Kusunoki T, Hailman E, Juan TS, Lichenstein HS, Wright SD: Molecules from Staphylococcus aureus that bind CD14 and stimulate innate immune responses. J Exp Med 182:1673, 1995
14. Weidemann B, Brade H, Rietschel ET, Dziarski R, Bazil V, Kusumoto S, Flad H-D, Ulmer AJ: Soluble peptidoglycan-induced monokine production can be blocked by anti-CD 14 monoclonal antibodies and by lipid A partial structures. Infect Immun 62:4709, 1994
15. Kusunoki T, Wright SD: Chemical characteristics of Staphylococcus aureus molecules that have CD14-dependent cell-stimulating activity. J Immunol 157:5112, 1996
16. Zhang Y, Doerfler M, Lee TC, Guillemin B, Rom WN: Mechanisms of stimulation of interleukin-1 beta and tumor necrosis factor-alpha by Mycobacterium tuberculosis components. J Clin Invest 91:2076, 1993
17. Savedra R Jr, Delude RL, Ingalls RR, Fenton MJ, Golenbock DT: Mycobacterial lipoarabinomannan recognition requires a receptor that shares components of the endotoxin signaling system. J Immunol 157:2549, 1996
18. Espevik T, Otterlei M, Skjåk-Bræk G, Ryan L, Wright SD, Sundan A: The involvement of CD14 in stimulation of cytokine production by uronic acid polymers. Eur J Immunol 23:255, 1993
19. Jahr TG, Ryan L, Sundan A, Lichenstein HS, Skjåk-Bræk G, Espevik T: Induction of tumor necrosis factor production from monocytes stimulated with mannuronic acid polymers and involvement of lipopolysaccharide- binding protein, CD14 and bacterial/permeability-increasing factor. Infect Immun 65:89, 1997
20. Yu B, Hailman E, Wright SD: Lipopolysaccharide binding protein and soluble CD14 catalyze exchange of phospholipids. J Clin Invest 99:315, 1997
21. Bosco MC, Espinoza-Delgado I, Rowe TK, Malabarba MG, Longo DL, Varesio L: Functional role for the myeloid differentiation antigen CD14 in the activation of human monocytes by IL-2. J Immunol 159:2922, 1997
22. Labeta MO, Durieux JJ, Fernandez N, Herrmann R, Ferrara P: Release from a human monocyte-like cell line of two different soluble forms of the lipopolysaccharide receptor, CD14. Eur J Immunol 23:2144, 1993
23. Bazil V, Strominger JL: Shedding as a mechanism of down-modulation of CD14 on stimulated human monocytes. J Immunol 147:1567, 1991
24. Durieux J-J, Vita N, Popescu O, Guette F, Calzada-Wack J, Munker R, Schmidt RE, Lupker J, Ferrara P, Ziegler-Heitbrock HWL, Labeta MO: The two soluble forms of the lipopolysaccharide receptor, CD14: Characterization and release by normal human monocytes. Eur J Immunol 24:2006, 1994
25. Landmann R, Knopf HP, Link S, Sansano S, Schumann R, Zimmerli W: Human monocyte CD14 is upregulated by lipopolysaccharide. Infect Immun 64:1762, 1996
26. Kruger C, Schutt C, Obertacke U, Joka T, Muller FE, Knoller J, Koller M, Konig W, Schonfeld W: Serum CD14 levels in polytraumatized and severely burned patients. Clin Exp Immunol 85:297, 1991
27. Landmann R, Zimmerli W, Sansano S, Link S, Hahn A, Glauser MP, Calandra T: Increased circulating soluble CD14 is associated with high mortality in gram-negative septic shock. J Infect Dis 171:639, 1995
28. Blanco A, Solis G, Arranz E, Goto GD, Ramos A, Telleria J: Serum levels of CD14 in neonatal sepsis by gram-positive and gram-negative bacteria. Acta Paediatr 85:728, 1996
29. Horneff G, Sack U, Kalden JR, Emmrich F, Burmester GR: Reduction of monocyte-macrophage activation markers upon anti-CD4 treatment. Decreased levels of IL-1, IL-6, neopterin and soluble CD14 in patients with rheumatoid arthritis. Clin Exp Immunol 91:207, 1993
30. Lorenz HM, Antoni C, Valerius T, Repp R, Grunke M, Schwerdtner N, Nusslein H, Woody J, Kalden JR, Manger B: In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects. J Immunol 156:1646, 1996
31. Nockher WA, Bergmann L, Scherberich JE: Increased soluble CD14 serum levels and altered CD14 expression of peripheral blood monocytes in HIV-infected patients. Clin Exp Immunol 98:369, 1994
32. Aukrust P, Liabakk NB, Müller F, Lien E, Espevik T, Frøland SS: Serum levels of tumor necrosis factor-alpha (TNF alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection -Correlations to clinical, immunologic, and virologic parameters. J Infect Dis 169:420, 1994 [erratum 169:1186, 1994]
33. Aukrust P, Liabakk NB, Müller F, Lien E, Espevik T, Frøland SS: Serum levels of tumor necrosis factor-alpha (TNF alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection -Correlations to clinical, immunologic, and virologic parameters. J Infect Dis 169:420, 1994 [erratum 169:1186, 1994]
34. Godfried MH, van der Poll T, Weverling GJ, Mulder JW, Jansen J, van Deventer SJ, Sauerwein HP: Soluble receptors for tumor necrosis factor as predictors of progression to AIDS in asymptomatic human immunodeficiency virus type I infection. J Infect Dis 169:739, 1994
35. Haug CJ, Aukrust P, Lien E, Müller F, Espevik T, Frøland SS: Disseminated Mycobacterium avium complex infection in AIDS: Immunopathogenic significance of an activated tumor necrosis factor system and depressed serum levels of 1,25 dihydroxyvitamin. J Infect Dis 173:259, 1996
36. Center for Disease Control and Prevention: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 41:1, 1992
37. Van Voorhis WC, Steinman RM, Hair LS, Luban J, Witmer MD, Koide S, Cohn ZA: Specific antimononuclear phagocyte monoclonal antibodies. Application to the purification of dendritic cells and the tissue localization of macrophages. J Exp Med 158:126, 1983
38. Brinchmann JE, Vartdal F, Gaudernack G, Markussen G, Funderud S, Ugelstad J, Thorsby E: Direct immunomagnetic quantification of lymphocyte subsets in blood. Clin Exp Immunol 71:182, 1988
39. The Council of Europe (Partial Agreement) in Accordance With the Convention of the Elaboration of an European Pharmacopoiea: Tuberculin purified protein derivative for human use, in European Pharmacopoeia. Sainte-Ruffine, France, Maisonneuve S.A., 1982, p 1982
40. Espevik T, Nissen-Meyer J: A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods 95:99, 1986
41. Bilello JA, Stellrecht K, Drusano GL, Stein DS: Soluble tumor necrosis factor-alpha receptor type II (sTNF alpha RII) correlates with human immunodeficiency virus (HIV) RNA copy number in HIV-infected patients. J Infect Dis 173:464, 1996
42. Drabick JJ, Williams WJ, Tang DB, Sun W, Chung RC: CD4 lymphocyte decline and survival in human immunodeficiency virus infection. The Military Medical Consortium for Applied Retroviral Research. AIDS Res Hum Retroviruses 8:2039, 1992
43. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272:1167, 1996
44. Wahl LM, Corcoran ML, Pyle SW, Arthur LO, Harel Bellan A, Farrar WL: Human immunodeficiency virus glycoprotein (gp120) induction of monocyte arachidonic acid metabolites and interleukin 1. Proc Natl Acad Sci USA 86:621, 1989
45. Clouse KA, Cosentino LM, Weih KA, Pyle SW Robbins PB, Hochstein HD, Natarajan V, Farrar WL: The HIV-1 gp120 envelope protein has the intrinsic capacity to stimulate monokine secretion. J Immunol 147:2892, 1991
46. Ehrenreich H, Rieckmann P, Sinowatz F, Weih KA, Arthur LO, Goebel FD, Burd PR, Coligan JE, Clouse KA: Potent stimulation of monocytic endothelin-1 production by HIV-1 glycoprotein 120. J Immunol 150:4601, 1993
47. Olsson I, Gatanaga T, Gullberg U, Lantz M, Granger GA: Tumour necrosis factor (TNF) binding proteins (soluble TNF Receptor forms) with possible roles in inflammation and malignancy. Eur Cytokine Netw 4:169, 1993
48. Diez- Ruiz A, Tilz GP, Zangerle R, Baier Bitterlich G, Wachter H, Fuchs D: Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur J Haematol 54:1, 1995
49. Gilben M, Kirihara J, Mills J: Enzyme-linked immunoassay for human immunodeficiency virus type 1 envelope glycoprotein 120. J Clin Microbiol 29:l42, 1991
50. Nightingale SD, Byrd LT, Southern PM, Jockusch JD, Cal SX, Wynne BA: Incidence of Mycobacterium avium- intracellulare complex bacteremia in human immunodeficiency virus-positive patients. J Infect Dis 165:1082, 1992
51. Denis M, Ghadirian E: Mycobacterium avium infection in HIV-1-infected subjects increases monokine secretion and is associated with enhanced viral load and diminished immune response to viral antigens. Clin Exp Immunol 97:76, 1994
52. Zerlauth G, Maier E, Chehadeh H, Zimmermann K, Eibl MM, Mannhalter JW: Interaction with human immunodeficiency virus type 1 modulates innate effector functions of human monocytes. J Infect Dis 172:1598, 1995
53. Shiratsuchi H, Johnson JL, Toossi Z, Ellner JJ: Modulation of the effector function of human monocytes for Mycobacterium avium by human immunodeficiency virus-1 envelope glycoprotein gp120. J Clin Invest 93:885, 1994
54. Bagasra O, Wright SD, Seshamma T, Oakes JW, Pomerantz RJ: CD14 is involved in control of human immunodeficiency virus type 1 expression in latently infected cells by lipopolysaccharide. Proc Natl Acad Sci USA 89:6285, 1992
55. Orenstein JM, Fox C, Wahl SM: Macrophages as a source of HIV during opportunistic infections. Science 276:1857, 1997
56. Haziot A, Ferrero E, Kontgen F, Hijiya N, Yamamoto S, Silver J, Stewart CL, Goyert SM: Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice. Immunity 4:407, 1996
57. Grunwald U, Fan X, Jack RS, Workalemahu G, Rallies A, Stelter F, Schutt C: Monocytes can phagocytose gram- negative bacteria by a CD 14-dependent mechanism. J Immunol 157:4119, 1996
58. Peterson PK, Gekker G, Hu S, Sheng WS, Anderson WR, Ulevitch RJ, Tobias PS, Gustafson KV, Molitor TW, Chao CC: CD14 receptor-media ted uptake of nonopsonized Mycobacterium tuberculosis by human microglia. Infect Immun 63:1598, 1995
59. Troelstra A, Giepmans BN, van Kessel KP, Lichenstein HS, Verhoef J, van Strijp JA: Dual effects of soluble CD14 on LPS priming of neutrophils. J Leukoc Biol 61:173, 1997
60. Nockher WA, Wigand R, Schoeppe W, Scherberich JE: Elevated levels of soluble CD14 in serum of patients with systemic lupus erythematosus. Clin Exp Immunol 96:15, 1994
61. Dalgleish AG: The immune response to HIV: Potential for immunotherapy? Immunol Today 16:356, 1995